HUE054271T2 - Mielóma Multiplex (MM) kezelése - Google Patents
Mielóma Multiplex (MM) kezeléseInfo
- Publication number
- HUE054271T2 HUE054271T2 HUE16723349A HUE16723349A HUE054271T2 HU E054271 T2 HUE054271 T2 HU E054271T2 HU E16723349 A HUE16723349 A HU E16723349A HU E16723349 A HUE16723349 A HU E16723349A HU E054271 T2 HUE054271 T2 HU E054271T2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- multiple myeloma
- myeloma
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title 2
- 208000034578 Multiple myelomas Diseases 0.000 title 1
- 201000000050 myeloid neoplasm Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597 | 2015-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054271T2 true HUE054271T2 (hu) | 2021-08-30 |
Family
ID=53174925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16723349A HUE054271T2 (hu) | 2015-05-13 | 2016-05-13 | Mielóma Multiplex (MM) kezelése |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (OSRAM) |
| EP (1) | EP3294769B1 (OSRAM) |
| JP (2) | JP7160533B2 (OSRAM) |
| KR (1) | KR20180008571A (OSRAM) |
| CN (1) | CN107614530A (OSRAM) |
| AU (1) | AU2016260895B2 (OSRAM) |
| CA (1) | CA2984464C (OSRAM) |
| CY (1) | CY1123982T1 (OSRAM) |
| DK (1) | DK3294769T3 (OSRAM) |
| ES (1) | ES2862708T3 (OSRAM) |
| HR (1) | HRP20210552T1 (OSRAM) |
| HU (1) | HUE054271T2 (OSRAM) |
| IL (1) | IL255552B (OSRAM) |
| LT (1) | LT3294769T (OSRAM) |
| MX (1) | MX380557B (OSRAM) |
| PL (1) | PL3294769T3 (OSRAM) |
| PT (1) | PT3294769T (OSRAM) |
| RS (1) | RS61668B1 (OSRAM) |
| RU (1) | RU2723047C2 (OSRAM) |
| SG (1) | SG11201708691VA (OSRAM) |
| SI (1) | SI3294769T1 (OSRAM) |
| SM (1) | SMT202100202T1 (OSRAM) |
| WO (1) | WO2016180958A1 (OSRAM) |
| ZA (1) | ZA201708386B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| MX380557B (es) * | 2015-05-13 | 2025-03-12 | Morphosys Ag | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). |
| JP7316930B2 (ja) | 2016-07-15 | 2023-07-28 | 武田薬品工業株式会社 | 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料 |
| CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| CA3095086A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| AU2019395841B2 (en) * | 2018-12-14 | 2025-02-27 | Morphosys Ag | Antibody formulations |
| JP7712206B2 (ja) * | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| EA037929B1 (ru) | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
| HUE035250T2 (hu) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása |
| PL2068874T3 (pl) * | 2006-08-07 | 2015-06-30 | Abbvie Biotherapeutics Inc | Sposoby leczenia szpiczaka mnogiego z użyciem terapii skojarzonych opartych na przeciwciałach anty-cs1 |
| ME03503B (me) * | 2006-09-26 | 2020-04-20 | Genmab As | Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SI2580243T1 (sl) * | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
| PL2621531T3 (pl) * | 2010-09-27 | 2017-07-31 | Morphosys Ag | Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL |
| WO2014089279A1 (en) * | 2012-12-05 | 2014-06-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| CA2927099A1 (en) * | 2013-10-31 | 2015-05-07 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| KR20210125603A (ko) | 2014-06-16 | 2021-10-18 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| MX380557B (es) * | 2015-05-13 | 2025-03-12 | Morphosys Ag | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). |
-
2016
- 2016-05-13 MX MX2017014396A patent/MX380557B/es unknown
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 SM SM20210202T patent/SMT202100202T1/it unknown
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en not_active Ceased
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Ceased
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256209A (en) | Novel cannabinoid combination therapies for multiple myeloma (mm) | |
| EP3359661A4 (en) | MULTIPLEXED GEMONEDITATION | |
| DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| HUE054271T2 (hu) | Mielóma Multiplex (MM) kezelése | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| EP3317241A4 (en) | THERAPEUTIC INHIBITING COMPOUNDS | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3302063T3 (da) | Fremgangsmåde til stimulering af frø | |
| EP3360010A4 (en) | BI PHOTONS WITH VOTABLE SOURCE | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| IL256111B1 (en) | Pac–1 combination therapy | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3307184T3 (da) | Implantatfjerner | |
| EP3259254A4 (en) | THERAPEUTIC COMPOUNDS | |
| DK3855181T3 (da) | Forbindelser til behandling af lipofuscinrelaterede sygdomme |